This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
The impact of neutralizing antibodies (NAbs) to interferon-beta (IFN-β) on clinical and imaging parameters in multiple sclerosis (MS) is reviewed. An effect on relapse rates and imaging parameters was noted in patients who tested positive for NAbs, but disability measures were unaffected or showed a trend toward improvement. Patients who developed NAbs during treatment with IFN-β1a tended to remain NAb+, whereas those who developed NAbs during IFN-β1b treatment tended to revert to NAb− over time. NAbs were more persistent in patients with high titers. The prevalence of NAbs was lower when a higher-than-standard dose of IFN-β1b was given in a dose-comparison study. The prevalence of NAbs in an observational study of MS patients who exhibited suboptimal treatment responses to IFN-β1b was significantly less than the reported prevalence in clinical trials. An immunoregulatory effect of immune complexes of cytokine and anticytokine antibodies is proposed to account for the variability of clinical responses seen in patients who develop NAbs to IFN-β1b.
Footnotes
-
Disclosure: Dr. Noronha receives research funding from Merck Serono S.A., Berlex, Inc., Biogen Idec, Schering AG, and Teva Neuroscience, Inc. Publication of this supplement was supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
Neurology® supplements are not peer-reviewed. Information contained in Neurology® supplements represents the opinions of the authors and is not endorsed by nor does it reflect the views of the American Academy of Neurology, Editorial Board, Editor-in-Chief, or Associate Editors of Neurology®.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
- Article
- Abstract
- NABS: BIOLOGICAL RESPONSE MARKERS AND ASSAYS
- NAB PREVALENCE IN MS CLINICAL TRIALS
- CLINICAL AND IMAGING PARAMETERS IN NAB+ PATIENTS
- PERSISTENCE OF NABS: HIGH-AFFINITY NABS IN IFN-β1A-TREATED PATIENTS
- SUBOPTIMAL TREATMENT RESPONSE TO INTERFERON
- IMMUNOREGULATORY EFFECTS OF NABS: IMMUNE COMPLEXES
- NOTE ADDED IN PROOF
- Footnotes
- REFERENCES
- Figures & Data
- Info & Disclosures
